Research advances in role of carvedilol in management of cirrhotic portal hypertension: a review of clinical trials
-
摘要: 降低门体压力梯度是预防肝硬化静脉曲张出血的首要目的。卡维地洛具有非选择性阻断β受体、阻断α1受体及阻断钙通道的作用。回顾了卡维地洛在降低门静脉压力梯度方面以及预防静脉曲张出血的作用。分析表明卡维地洛较普萘洛尔可以更有效地降低门体压力梯度。卡维地洛与普萘洛尔或内镜套扎预防静脉曲张首次及再次出血疗效是相似的。未来大样本随机对照试验应该证实这些研究结果。Abstract: The primary aim of preventing variceal bleeding in liver cirrhosis is to reduce portosystemic pressure gradient. Carvedilol is a non- selective beta blocker with selective inhibition of α- 1 receptor and blockage of calcium channel. This paper reviews the role of carvedilol in reducing hepatic venous pressure gradient and preventing variceal bleeding. Analysis has shown that carvedilol is superior to propranolol in reducing portosystemic pressure gradient. Carvedilol may be similar to propranolol or endoscopic ligation for the primary and secondary prevention of variceal bleeding. Further randomized controlled trials with a larger sample size are warranted to confirm these findings.
-
Key words:
- liver cirrhosis /
- hypertension,portal /
- esophageal and gastric varices /
- carvedilol /
- review
本文二维码
计量
- 文章访问数: 3306
- HTML全文浏览量: 17
- PDF下载量: 589
- 被引次数: 0